Currently, almost 60 percent of drugs in development are being created by emerging biotech companies focused on therapies for niche diseases with small patient...
In this GEN webinar, we will discuss how the VIPS™ (Verified in-situ Plate Seeding) system, in combination with the SAL Scientific single-cell cloning supplements, offer customers a high-efficiency solution which ensures plates are populated with high numbers of healthy single cells that grow into resultant colonies for screening, expansion and further selection to master cell banks.
REGISTER NOW Broadcast Date: February 5, 2019Time: 8:00 am PT, 11:00 am ET, 17:00 CET Antibody-drug conjugates select ADCs) were initially developed to provide a selective targeting mechanism...
In this GEN webinar, we will discuss some typical workflows used to characterize the properties of vaccines, looking at properties such as particle size, surface charge, aggregation, and protein secondary structure.
Join us for Episode 4 of GEN Live, sponsored by Tecan. In this live zoom event we discuss the state of vaccine development for COVID-19. We evaluate the front-runners, explore the potential of RNA vaccines, ponder the challenges of manufacturing, and tackle questions about herd immunity.
In this GEN webinar, we will review pressure-assisted protein refolding and pressure perturbation coupled with MMS to study protein stability in biopharmaceutical formulations.
In this GEN webinar, sponsored by Carterra, we will demonstrate how modern day high-throughput surface plasmon resonance (HT-SPR™) has facilitated a paradigm shift in antibody screening, enabling higher information content assays to be conducted earlier in the research pipeline to streamline lead selection. This essentially combines screening and detailed characterization in the same step, condensing months of work into days.
In this GEN webinar, sponsored by Berkeley Lights, we will hear from Anupam Singhal, PhD, who will provide a brief overview of how antibody discovery on the Beacon optofluidic system can be used to screen human B cells for the discovery of antiviral antibodies in under one week. Robert Carnahan, PhD, and Seth Zost, PhD, from the Vanderbilt University Medical Center, will then describe how they have used the Beacon system, to rapidly discover hundreds of unique antibodies against SARS-CoV-2.